Trials / Recruiting
RecruitingNCT06178614
A Study of JNJ-87890387 for Advanced Solid Tumors
A Phase 1 Study of JNJ-87890387, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 (ENPP3) x CD3 Bispecific Antibody, for Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-87890387 | JNJ-87890387 will be administered. |
Timeline
- Start date
- 2023-12-14
- Primary completion
- 2027-03-16
- Completion
- 2029-02-07
- First posted
- 2023-12-21
- Last updated
- 2026-04-13
Locations
6 sites across 3 countries: United States, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06178614. Inclusion in this directory is not an endorsement.